Tag: executive

Limassol, Cyprus, July 14, 2025 (GLOBE NEWSWIRE) -- Cyprus-based Innoventure Global Partners Ltd. is making waves across the Asian market with its pioneering “investment + deep incubation” model—signaling a major move into Southeast Asia’s rapidly growing digital economy sector.

Innoventure has built a robust network of strategic partners across Asia and Europe. Its unique LP + GP structure sets it apart:

Limited Partners (LPs) contribute strategic insights and capital backing

General Partners (GPs) lead project selection, market execution, and operational management




This dual-engine model allows Innoventure to balance agility with professional risk control, especially in fast-evolving sectors such as AI-driven social commerce, digital economy, and next-generation consumer technology.

As part of its global expansion strategy, Innoventure is now establishing a strong presence across Southeast Asia. The company’s flagship initiative, NOVALUXIA, is gaining momentum in the region and has already attracted attention from leading tech innovators and regional government bodies. Designed around the principle of “tech-driven innovation powered by user co-creation,” NOVALUXIA exemplifies Innoventure’s mission to align international capital with local market needs.

“Innoventure is not just funding innovation—it’s building the future through sustained partnerships and visionary execution,”
— Executive Director, European Consumer Tech Fund

Looking ahead, Innoventure Global Partners Ltd. plans to extend its incubation ecosystem into key emerging markets across Southeast Asia, Africa, and Latin America. By fusing global resources with local innovation, Innoventure aims to accelerate digital transformation and contribute to building a more inclusive and interconnected global economy.

Media Contact

Contact: DENNIS TING YUK SHIN

Company Name: Innoventure Global Partners Ltd.

Website: https://novaluxia.com/

Email: Dapchiew@novaluxia.com

Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”) in an offshore transaction outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”)(the “Offshore Placement”), for aggregate gross proceeds of approximately HKD1,509.2 million (or approximately US$192.3 million based on exchange rate of 1 USD to 7.85 HKD), before deducting placing fees and other offering expenses. The Offshore Placement, which was oversubscribed by eight times, is expected to close on July 17, 2025.

EDMONTON, Alberta, July 14, 2025 (GLOBE NEWSWIRE) -- Capital Power Corporation (TSX: CPX) is pleased to announce Ferio Pugliese has joined the company as Senior Vice President, Chief Corporate Officer, effective today. Mr. Pugliese succeeds Jacquie Pylypiuk.

SALT LAKE CITY, July 14, 2025 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, has completed the Company’s previously announced sale of PIEPS and assets of the JetForce avalanche pack intellectual property to a private investment firm for a total purchase price of €7.8 million, or approximately $9.1 million, including cash and debt.

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025